Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.685 USD | -20.47% | +156.95% | +232.76% |
May. 31 | Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday | MT |
May. 31 | Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 70.45 | 282.7 | 1,437 | 4,792 | - | - |
Enterprise Value (EV) 1 | 70.45 | 282.7 | 1,437 | 4,792 | 4,792 | 4,792 |
P/E ratio | -9.28 x | - | -2.62 x | - | - | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 4.47 x | 19.4 x | - | - | - | 487 x |
EV / Revenue | 4.47 x | 19.4 x | - | - | - | 487 x |
EV / EBITDA | - | - | - | -34.8 x | -30.6 x | -27.9 x |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 335,890 | 82,260 | 700,843 | 701,980 | - | - |
Reference price 2 | 1.207 | 3.437 | 2.050 | 6.826 | 6.826 | 6.826 |
Announcement Date | 4/30/20 | 3/17/21 | 2/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | 15.75 | 14.54 | - | - | - | 9.841 |
EBITDA 1 | - | - | - | -137.5 | -156.6 | -171.6 |
EBIT 1 | -25.33 | -38.35 | - | -143.9 | -174.2 | -217.1 |
Operating Margin | -160.88% | -263.7% | - | - | - | -2,206.03% |
Earnings before Tax (EBT) | -25.56 | - | - | - | - | - |
Net income | -22.03 | - | -486.2 | - | - | - |
Net margin | -139.92% | - | - | - | - | - |
EPS | -0.1300 | - | -0.7828 | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/30/20 | 3/17/21 | 2/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA 1 | - | -35.08 | -34.66 | -34.33 | - | - |
EBIT 1 | -33.85 | -35.98 | -36.96 | -37.18 | -41.62 | -44.02 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - |
Net income | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - |
EPS | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 5/1/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | -155% | -100% | -135% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | - | - | - | - | 0.08 |
Capex / Sales | - | - | - | - | - | 0.8% |
Announcement Date | 4/30/20 | 3/17/21 | 2/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+232.76% | 6.1B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SMMT Stock
- Financials Summit Therapeutics Inc.